Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Replication-deficient adenoviruses are potent vaccine development platforms used extensively for human and animal candidate vaccines, largely due to their very good safety and immunogenicity profile. In this chapter we describe a method that can be used in any laboratory for the scalable production of replication-deficient adenovirus vector vaccines to GLP for preclinical studies in animal models, including definitive experimental studies in large target animal species for veterinary applications. We use human adenovirus serotype 5 (HAdV5) as an example, but the method can be easily adapted for use with other adenovirus serotypes from different species of origin.

Original publication

DOI

10.1007/978-1-4939-3008-1_8

Type

Chapter

Publication Date

01/2016

Volume

1349

Pages

121 - 135

Addresses

The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ, UK. susan.morris@ndm.ox.ac.uk.

Keywords

Animals, Humans, Adenoviruses, Human, Antibodies, Viral, Vaccination, Virus Replication, Genome, Viral, Genetic Vectors, HEK293 Cells, Adenovirus Vaccines